PMA supplement
P240010 S009: MI Cancer Seek®
FDA PMA supplement · 30-Day Notice · Caris Life Sciences
Key facts
| Original PMA | P240010 |
|---|---|
| Supplement number | S009 |
| Supplement type | 30-Day Notice |
| Reason for the supplement | Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| Trade name | MI Cancer Seek® |
| Generic name | Next generation sequencing oncology panel, somatic or germline variant detection system |
| Applicant | Caris Life Sciences |
| Product code | PQP |
| Received date | Apr 30, 2026 |
| Decision date | May 28, 2026 |
At a glance
- No Expedited review granted
- No Approval order on file
- No Summary of safety and effectiveness on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA supplements
A PMA supplement asks FDA to approve a change to a device that already holds a premarket approval: a new indication, a design or labeling change, a manufacturing site or process change.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: